

Dear Cutera Partner,

As a valued partner of Cutera, I am reaching out to provide an important update about our business. For more than 25 years, Cutera has been at the forefront of the industry, delivering effective and innovative solutions that help providers offer the best possible care to their patients around the globe. We're proud of what we've built, but we're also constantly evolving to better meet the needs of our customers and their patients.

Like many companies in the current environment, we've been navigating macroeconomic pressures that have impacted our financial position. We've implemented a number of operational initiatives to strengthen the Company and enhance our ability to serve you, and we're already seeing successful momentum from these efforts. The final step, though, is to address the level of debt that the Company is carrying. Today, we've reached an agreement with a group of existing lenders, who own our convertible debt, to reduce our debt position by nearly \$400 million, or over 90%, and to inject significant new capital into the business. This is exactly what we need to strengthen our financial foundation and position Cutera for future success.

We determined that the best way to implement this transaction is through a voluntary "prepackaged" form of the Chapter 11 process. Because we have already reached an agreement with the vast majority of our lenders, this process will be quick and efficient and we expect to complete the process within 60 days. At the end of the process, Cutera will be a private company with a much stronger capital structure and the backing of a large consortium of leading investment firms.

**Most importantly, we are operating as usual and serving you remains our top priority.** Here are the most important things for you to know:

- **There are no changes to product availability, service, support, or anything else related to our day-to-day operations.** You will continue to receive innovative solutions, as well as the support and service you deserve.
- **Orders are being fulfilled and completed as usual.** Furthermore, this process does not impact Cutera approved clinical trials or studies.
- **We have sufficient liquidity to support Cutera through this process and beyond.** We have received commitments for \$65 million in new financing, which will help enable our ongoing operations and support our go-forward business upon emergence.

We are committed to transparent and consistent communications and will continue to provide you updates as there is news to share. Additionally, you may receive legal notices from Verita, a third-party supporting us during this process—these communications are typical of the Chapter 11 process. If you have any questions, please reach out to our customer support team at [StrengtheningCutera@cutera.com](mailto:StrengtheningCutera@cutera.com). You can also visit <https://cutera.com/strengtheningcutera> for additional information.

We are optimistic about our future and look forward to all we can—and will—achieve for you and your patients. Thank you for your continued partnership.

Best regards,



Taylor Harris  
Chief Executive Officer